Canada's Apotex Donates Critical N95 Masks to Support Frontline Healthcare Workers
Apr 17, 2020
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Jul 2, 2025
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc., the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization.
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 1, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.